Ribomic Inc.
Stock Price Chart
2026/10/07 19:11 UpdatedPrice Trend
2026/10/07 19:11 UpdatedPrice & Trading Details
2026/10/07 19:11 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2025 | 2026 | |
|---|---|---|---|
| Income Statement | |||
| Revenue | ¥66M | ¥2M | ¥3M |
| Gross Profit | - | - | - |
| Operating Income | -¥1,786M | -¥1,051M | -¥1,207M |
| Pretax Income | -¥1,786M | -¥1,051M | -¥1,207M |
| Net Income | -¥1,653M | -¥1,019M | -¥1,145M |
| EPS | -¥53.14 | -¥25.21 | -¥23.07 |
| Operating Margin | -2,707.39% | -49,861.84% | -40,237.73% |
| Balance Sheet | |||
| Total Assets | ¥4,584M | ¥3,186M | ¥2,976M |
| Total Equity | ¥4,384M | ¥3,044M | ¥2,841M |
| Total Liabilities | ¥199M | ¥142M | ¥135M |
| Cash | ¥2,825M | ¥1,837M | ¥1,927M |
| Interest-bearing Debt | - | - | - |
| Equity Ratio | 95.65% | 95.54% | 95.46% |
| D/E Ratio | 0.00 | 0.00 | 0.00 |
| Cash Flow | |||
| Operating CF | -¥1,709M | -¥997M | -¥1,111M |
| Investing CF | ¥276M | ¥67M | ¥290M |
| Financing CF | ¥1,334M | ¥667M | ¥911M |
| Free CF | -¥1,733M | -¥1,030M | -¥1,121M |
| Efficiency | |||
| ROE | -37.70% | -33.48% | -40.31% |
| ROA | -36.06% | -31.98% | -38.48% |
Latest IR Information
-
Announcement on Progress of Phase II Long-Term Dosing Trial of Umedaptanib Pegol for Achondroplasia and Continued Efficacy in Responding Patients
Reports progress of the Phase II long-term dosing trial and continued height growth effects in responding patients. AGV improvement was observed in patients with long-term dosing who responded, while non-responders showed no sustained effect. Monitor potential future dose adjustments. No...
Read more -
Notice Regarding Monthly Exercise Status of the 19th Stock Acquisition Rights Issued by Third-Party Allotment (with Exercise Price Adjustment Clause)
Published the monthly exercise status for September 2026. Delivered shares: 260,000 shares; stock acquisition rights exercised in September: 2,600 units; ratio to total issued: 2.4%; unexercised rights at the end of the subject month: 8,500,000 shares; exercise resumed from September...
Read more -
Notice on Change in Dosing Regimen (1 mg/kg Once Weekly) and Safety in Domestic Phase II Long-Term Dosing Trial
In the domestic Phase II long-term dosing trial, the first subjects who transitioned to 1 mg/kg once-weekly dosing showed no new safety concerns up to three months after transition, and long-term safety data will be supplemented to the WAKABA trial....
Read more -
Notice on Progress of Subject Enrollment in Domestic Phase III Clinical Trial of Osteogenesis Imperfecta Treatment (umedaptanib pegol) (WAKABA Study)
Enrollment of two additional subjects completed in the domestic Phase III trial (WAKABA) using the new drug ume daptanib pegol, bringing total to three. Trial conducted at 16 sites with patient enrollment proceeding as planned. No impact on the FY2027...
Read more -
Domestic Phase 3 Clinical Trial for Treatment of Achondroplasia (umedaptanib pegol): Expansion of Participating Medical Institutions Completed (planned number of facilities reached)
Expansion of the clinical trial infrastructure to accelerate subject enrollment has been completed. IRB approvals obtained for six new facilities, bringing total participating sites to 16. No impact on the 2027 fiscal year results.
Read more
Latest News (5 items)
Company Information
About
Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema. It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glaucoma, and diabetic retinopathy; RBM-011 for the treatment of pulmonary arterial hypertension; RBM-003 for the treatment of heart failure; RBM-010 for the treatment of osteoarthritis; and RBM-009 for the treatment of severe asthma, as well as RBM-101, which is in discovery stage for the affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Minato, Japan.
